Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

PURPOSE: Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy. The addition of the Bruton tyrosine kinase (BTK)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Chemother Pharmacol
Prif Awduron: Pilla Reddy , Venkatesh, Fretland, Adrian J., Zhou, Diansong, Sharma, Shringi, Chen, Buyun, Vishwanathan, Karthick, McGinnity, Dermot F., Xu, Yan, Ware, Joseph A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2021
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316236/
https://ncbi.nlm.nih.gov/pubmed/34080039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04302-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg